A. Cabranes

Most-cited papers

1. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

   A. Cabranes, K. Venderová, E. de Lago, F. Fezza +7 more

   2005Neurobiology of Disease131 citations Open access

   Semantic Scholar

   Save

2. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake.

   E. de Lago, A. Ligresti, G. Ortar, E. Morera +6 more

   2004European Journal of Pharmacology100 citations

   Semantic Scholar

   Save

3. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.

   E. de Lago, M. Moreno-Martet, A. Cabranes, J. Ramos +1 more

   2012Neuropharmacology75 citations

   Semantic Scholar

   Save

4. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

   E. de Lago, J. Fernández-Ruiz, S. Ortega-Gutiérrez, A. Cabranes +4 more

   2006European Neuropsychopharmacology75 citations

   Semantic Scholar

   Save

5. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis

   F. Berrendero, Antonio J. Sánchez, A. Cabranes, C. Puerta +3 more

   2001Synapse66 citations

   Semantic Scholar

   Save

6. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.

   A. Cabranes, G. Pryce, D. Baker, J. Fernández-Ruiz

   2006Brain Research32 citations

   Semantic Scholar

   Save

7. Involvement of the Endocannabinoid System in Motor Disorders

   J. Fernández-Ruiz, I. Lastres-Becker, A. Cabranes, E. de Lago +1 more

   20042 citations

   Semantic Scholar

   Save